nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—sarcoma	0.884	1	CbGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—FLI1—sarcoma	0.00896	0.239	CbGpPWpGaD
Plerixafor—CXCR4—endothelium—sarcoma	0.00613	0.137	CbGeAlD
Plerixafor—CXCR4—mammary gland—sarcoma	0.00494	0.111	CbGeAlD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—CSF3—sarcoma	0.00424	0.113	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—FLT1—sarcoma	0.00374	0.0996	CbGpPWpGaD
Plerixafor—CXCR4—myometrium—sarcoma	0.0035	0.0785	CbGeAlD
Plerixafor—CXCR4—embryo—sarcoma	0.00337	0.0755	CbGeAlD
Plerixafor—CXCR4—seminal vesicle—sarcoma	0.00317	0.0709	CbGeAlD
Plerixafor—CXCR4—hematopoietic system—sarcoma	0.00301	0.0674	CbGeAlD
Plerixafor—CXCR4—connective tissue—sarcoma	0.0029	0.0649	CbGeAlD
Plerixafor—CXCR4—smooth muscle tissue—sarcoma	0.00265	0.0593	CbGeAlD
Plerixafor—CXCR4—S1P3 pathway—PDGFRB—sarcoma	0.0026	0.0693	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.0023	0.0613	CbGpPWpGaD
Plerixafor—CXCR4—cardiac atrium—sarcoma	0.00228	0.0512	CbGeAlD
Plerixafor—CXCR4—uterus—sarcoma	0.00227	0.0509	CbGeAlD
Plerixafor—CXCR4—lymphoid tissue—sarcoma	0.00212	0.0474	CbGeAlD
Plerixafor—CXCR4—tendon—sarcoma	0.00199	0.0446	CbGeAlD
Plerixafor—CXCR4—bone marrow—sarcoma	0.00193	0.0432	CbGeAlD
Plerixafor—CXCR4—testis—sarcoma	0.00165	0.0369	CbGeAlD
Plerixafor—CXCR4—liver—sarcoma	0.00156	0.0349	CbGeAlD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PTPRC—sarcoma	0.00142	0.0379	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—PDGFRA—sarcoma	0.00141	0.0374	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—SRC—sarcoma	0.00122	0.0325	CbGpPWpGaD
Plerixafor—CXCR4—lymph node—sarcoma	0.00119	0.0268	CbGeAlD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—sarcoma	0.00119	0.0317	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KDR—sarcoma	0.00118	0.0315	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KIT—sarcoma	0.00109	0.029	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—FOXO1—sarcoma	0.000989	0.0263	CbGpPWpGaD
Plerixafor—Induration—Etoposide—sarcoma	0.000976	0.0287	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—NPM1—sarcoma	0.000891	0.0237	CbGpPWpGaD
Plerixafor—Platelet count decreased—Mitoxantrone—sarcoma	0.000882	0.0259	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.00087	0.0232	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—JUN—sarcoma	0.000626	0.0167	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.000547	0.0146	CbGpPWpGaD
Plerixafor—Musculoskeletal pain—Vincristine—sarcoma	0.000545	0.016	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—SRC—sarcoma	0.000463	0.0123	CbGpPWpGaD
Plerixafor—Inflammation—Etoposide—sarcoma	0.00045	0.0132	CcSEcCtD
Plerixafor—Swelling—Mitoxantrone—sarcoma	0.000432	0.0127	CcSEcCtD
Plerixafor—Swelling—Etoposide—sarcoma	0.000359	0.0106	CcSEcCtD
Plerixafor—Haemoglobin—Thiotepa—sarcoma	0.000307	0.00901	CcSEcCtD
Plerixafor—Haemorrhage—Thiotepa—sarcoma	0.000305	0.00897	CcSEcCtD
Plerixafor—Connective tissue disorder—Thiotepa—sarcoma	0.0003	0.00881	CcSEcCtD
Plerixafor—Immune system disorder—Thiotepa—sarcoma	0.000276	0.0081	CcSEcCtD
Plerixafor—Mental disorder—Thiotepa—sarcoma	0.000267	0.00786	CcSEcCtD
Plerixafor—Connective tissue disorder—Vincristine—sarcoma	0.000266	0.00782	CcSEcCtD
Plerixafor—Erythema—Thiotepa—sarcoma	0.000266	0.00781	CcSEcCtD
Plerixafor—Haemoglobin—Mitoxantrone—sarcoma	0.000265	0.00778	CcSEcCtD
Plerixafor—Erythema—Dactinomycin—sarcoma	0.000264	0.00775	CcSEcCtD
Plerixafor—Haemorrhage—Mitoxantrone—sarcoma	0.000263	0.00775	CcSEcCtD
Plerixafor—Inflammation—Epirubicin—sarcoma	0.000252	0.00741	CcSEcCtD
Plerixafor—Musculoskeletal pain—Epirubicin—sarcoma	0.000248	0.00728	CcSEcCtD
Plerixafor—Ill-defined disorder—Dactinomycin—sarcoma	0.000245	0.00719	CcSEcCtD
Plerixafor—Injection site reaction—Epirubicin—sarcoma	0.000243	0.00715	CcSEcCtD
Plerixafor—CXCR4—Disease—TLE1—sarcoma	0.000242	0.00644	CbGpPWpGaD
Plerixafor—Malaise—Dactinomycin—sarcoma	0.000238	0.00699	CcSEcCtD
Plerixafor—Mental disorder—Vincristine—sarcoma	0.000237	0.00697	CcSEcCtD
Plerixafor—Inflammation—Doxorubicin—sarcoma	0.000233	0.00686	CcSEcCtD
Plerixafor—Erythema—Mitoxantrone—sarcoma	0.000229	0.00674	CcSEcCtD
Plerixafor—Musculoskeletal pain—Doxorubicin—sarcoma	0.000229	0.00673	CcSEcCtD
Plerixafor—Arthralgia—Thiotepa—sarcoma	0.000226	0.00665	CcSEcCtD
Plerixafor—Injection site reaction—Doxorubicin—sarcoma	0.000225	0.00661	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000225	0.0066	CcSEcCtD
Plerixafor—Discomfort—Dactinomycin—sarcoma	0.000222	0.00652	CcSEcCtD
Plerixafor—CXCR4—Disease—NPM1—sarcoma	0.000218	0.00581	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Mitoxantrone—sarcoma	0.000213	0.00626	CcSEcCtD
Plerixafor—Nervous system disorder—Thiotepa—sarcoma	0.000213	0.00625	CcSEcCtD
Plerixafor—Skin disorder—Thiotepa—sarcoma	0.000211	0.00619	CcSEcCtD
Plerixafor—Malaise—Mitoxantrone—sarcoma	0.000207	0.00608	CcSEcCtD
Plerixafor—Immune system disorder—Etoposide—sarcoma	0.000198	0.00582	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000197	0.00581	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000196	0.00576	CcSEcCtD
Plerixafor—Arthralgia—Mitoxantrone—sarcoma	0.000195	0.00574	CcSEcCtD
Plerixafor—Paraesthesia—Thiotepa—sarcoma	0.000195	0.00572	CcSEcCtD
Plerixafor—Discomfort—Mitoxantrone—sarcoma	0.000193	0.00567	CcSEcCtD
Plerixafor—Anaphylactic shock—Vincristine—sarcoma	0.000192	0.00565	CcSEcCtD
Plerixafor—Dyspepsia—Thiotepa—sarcoma	0.000191	0.00561	CcSEcCtD
Plerixafor—CXCR4—Disease—ENO2—sarcoma	0.000189	0.00504	CbGpPWpGaD
Plerixafor—Nervous system disorder—Vincristine—sarcoma	0.000188	0.00554	CcSEcCtD
Plerixafor—Anaphylactic shock—Mitoxantrone—sarcoma	0.000187	0.0055	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Thiotepa—sarcoma	0.000187	0.0055	CcSEcCtD
Plerixafor—Fatigue—Thiotepa—sarcoma	0.000187	0.00549	CcSEcCtD
Plerixafor—Hyperhidrosis—Vincristine—sarcoma	0.000186	0.00546	CcSEcCtD
Plerixafor—Fatigue—Dactinomycin—sarcoma	0.000185	0.00545	CcSEcCtD
Plerixafor—Constipation—Thiotepa—sarcoma	0.000185	0.00545	CcSEcCtD
Plerixafor—Pain—Thiotepa—sarcoma	0.000185	0.00545	CcSEcCtD
Plerixafor—Shock—Mitoxantrone—sarcoma	0.000184	0.00541	CcSEcCtD
Plerixafor—Pain—Dactinomycin—sarcoma	0.000184	0.00541	CcSEcCtD
Plerixafor—Skin disorder—Mitoxantrone—sarcoma	0.000182	0.00534	CcSEcCtD
Plerixafor—Hyperhidrosis—Mitoxantrone—sarcoma	0.000181	0.00532	CcSEcCtD
Plerixafor—Feeling abnormal—Thiotepa—sarcoma	0.000179	0.00525	CcSEcCtD
Plerixafor—Feeling abnormal—Dactinomycin—sarcoma	0.000177	0.00521	CcSEcCtD
Plerixafor—Gastrointestinal pain—Thiotepa—sarcoma	0.000177	0.00521	CcSEcCtD
Plerixafor—Ill-defined disorder—Etoposide—sarcoma	0.000177	0.0052	CcSEcCtD
Plerixafor—Gastrointestinal pain—Dactinomycin—sarcoma	0.000176	0.00517	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vincristine—sarcoma	0.000175	0.00515	CcSEcCtD
Plerixafor—Insomnia—Vincristine—sarcoma	0.000174	0.00511	CcSEcCtD
Plerixafor—Paraesthesia—Vincristine—sarcoma	0.000173	0.00507	CcSEcCtD
Plerixafor—Urticaria—Thiotepa—sarcoma	0.000172	0.00506	CcSEcCtD
Plerixafor—Malaise—Etoposide—sarcoma	0.000172	0.00506	CcSEcCtD
Plerixafor—Abdominal pain—Thiotepa—sarcoma	0.000171	0.00504	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000171	0.00501	CcSEcCtD
Plerixafor—Abdominal pain—Dactinomycin—sarcoma	0.00017	0.005	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TLE1—sarcoma	0.00017	0.00451	CbGpPWpGaD
Plerixafor—Paraesthesia—Mitoxantrone—sarcoma	0.000168	0.00494	CcSEcCtD
Plerixafor—Loss of consciousness—Etoposide—sarcoma	0.000168	0.00493	CcSEcCtD
Plerixafor—Dyspnoea—Mitoxantrone—sarcoma	0.000167	0.00491	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Vincristine—sarcoma	0.000166	0.00488	CcSEcCtD
Plerixafor—Fatigue—Vincristine—sarcoma	0.000166	0.00487	CcSEcCtD
Plerixafor—Dyspepsia—Mitoxantrone—sarcoma	0.000165	0.00484	CcSEcCtD
Plerixafor—Constipation—Vincristine—sarcoma	0.000164	0.00483	CcSEcCtD
Plerixafor—Pain—Vincristine—sarcoma	0.000164	0.00483	CcSEcCtD
Plerixafor—Orthostatic hypotension—Epirubicin—sarcoma	0.000162	0.00477	CcSEcCtD
Plerixafor—Fatigue—Mitoxantrone—sarcoma	0.000161	0.00474	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000161	0.00474	CcSEcCtD
Plerixafor—CXCR4—Disease—PLCG1—sarcoma	0.00016	0.00427	CbGpPWpGaD
Plerixafor—Discomfort—Etoposide—sarcoma	0.00016	0.00472	CcSEcCtD
Plerixafor—Pain—Mitoxantrone—sarcoma	0.00016	0.00471	CcSEcCtD
Plerixafor—Constipation—Mitoxantrone—sarcoma	0.00016	0.00471	CcSEcCtD
Plerixafor—Hypersensitivity—Thiotepa—sarcoma	0.00016	0.00469	CcSEcCtD
Plerixafor—Hypersensitivity—Dactinomycin—sarcoma	0.000158	0.00466	CcSEcCtD
Plerixafor—Gastrointestinal pain—Vincristine—sarcoma	0.000157	0.00462	CcSEcCtD
Plerixafor—Anaphylactic shock—Etoposide—sarcoma	0.000156	0.00458	CcSEcCtD
Plerixafor—Asthenia—Thiotepa—sarcoma	0.000156	0.00457	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—sarcoma	0.000155	0.00454	CcSEcCtD
Plerixafor—Asthenia—Dactinomycin—sarcoma	0.000154	0.00454	CcSEcCtD
Plerixafor—Feeling abnormal—Mitoxantrone—sarcoma	0.000154	0.00453	CcSEcCtD
Plerixafor—Pruritus—Thiotepa—sarcoma	0.000153	0.00451	CcSEcCtD
Plerixafor—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000153	0.0045	CcSEcCtD
Plerixafor—Abdominal pain—Vincristine—sarcoma	0.000152	0.00447	CcSEcCtD
Plerixafor—Skin disorder—Etoposide—sarcoma	0.000151	0.00445	CcSEcCtD
Plerixafor—Hyperhidrosis—Etoposide—sarcoma	0.000151	0.00442	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—sarcoma	0.00015	0.00441	CcSEcCtD
Plerixafor—Urticaria—Mitoxantrone—sarcoma	0.000149	0.00437	CcSEcCtD
Plerixafor—Diarrhoea—Thiotepa—sarcoma	0.000148	0.00436	CcSEcCtD
Plerixafor—Abdominal pain—Mitoxantrone—sarcoma	0.000148	0.00435	CcSEcCtD
Plerixafor—Diarrhoea—Dactinomycin—sarcoma	0.000147	0.00433	CcSEcCtD
Plerixafor—Dizziness—Thiotepa—sarcoma	0.000143	0.00421	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—VEGFC—sarcoma	0.000143	0.00381	CbGpPWpGaD
Plerixafor—Abdominal distension—Doxorubicin—sarcoma	0.000143	0.0042	CcSEcCtD
Plerixafor—Hypersensitivity—Vincristine—sarcoma	0.000142	0.00416	CcSEcCtD
Plerixafor—Paraesthesia—Etoposide—sarcoma	0.00014	0.00411	CcSEcCtD
Plerixafor—Dyspnoea—Etoposide—sarcoma	0.000139	0.00408	CcSEcCtD
Plerixafor—Hypersensitivity—Mitoxantrone—sarcoma	0.000138	0.00405	CcSEcCtD
Plerixafor—Asthenia—Vincristine—sarcoma	0.000138	0.00405	CcSEcCtD
Plerixafor—Vomiting—Thiotepa—sarcoma	0.000138	0.00405	CcSEcCtD
Plerixafor—Vomiting—Dactinomycin—sarcoma	0.000137	0.00402	CcSEcCtD
Plerixafor—Rash—Thiotepa—sarcoma	0.000137	0.00402	CcSEcCtD
Plerixafor—Dermatitis—Thiotepa—sarcoma	0.000137	0.00401	CcSEcCtD
Plerixafor—Headache—Thiotepa—sarcoma	0.000136	0.00399	CcSEcCtD
Plerixafor—Rash—Dactinomycin—sarcoma	0.000136	0.00399	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Etoposide—sarcoma	0.000134	0.00395	CcSEcCtD
Plerixafor—Asthenia—Mitoxantrone—sarcoma	0.000134	0.00395	CcSEcCtD
Plerixafor—Fatigue—Etoposide—sarcoma	0.000134	0.00395	CcSEcCtD
Plerixafor—Pain—Etoposide—sarcoma	0.000133	0.00391	CcSEcCtD
Plerixafor—Constipation—Etoposide—sarcoma	0.000133	0.00391	CcSEcCtD
Plerixafor—Diarrhoea—Vincristine—sarcoma	0.000132	0.00387	CcSEcCtD
Plerixafor—Nausea—Thiotepa—sarcoma	0.000129	0.00378	CcSEcCtD
Plerixafor—Feeling abnormal—Etoposide—sarcoma	0.000128	0.00377	CcSEcCtD
Plerixafor—Diarrhoea—Mitoxantrone—sarcoma	0.000128	0.00376	CcSEcCtD
Plerixafor—Nausea—Dactinomycin—sarcoma	0.000128	0.00376	CcSEcCtD
Plerixafor—Gastrointestinal pain—Etoposide—sarcoma	0.000127	0.00374	CcSEcCtD
Plerixafor—Dizziness—Vincristine—sarcoma	0.000127	0.00374	CcSEcCtD
Plerixafor—Urticaria—Etoposide—sarcoma	0.000124	0.00364	CcSEcCtD
Plerixafor—Haemoglobin—Epirubicin—sarcoma	0.000123	0.00363	CcSEcCtD
Plerixafor—Abdominal pain—Etoposide—sarcoma	0.000123	0.00362	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—sarcoma	0.000123	0.00361	CcSEcCtD
Plerixafor—Vomiting—Vincristine—sarcoma	0.000122	0.00359	CcSEcCtD
Plerixafor—Rash—Vincristine—sarcoma	0.000121	0.00356	CcSEcCtD
Plerixafor—Dermatitis—Vincristine—sarcoma	0.000121	0.00356	CcSEcCtD
Plerixafor—Connective tissue disorder—Epirubicin—sarcoma	0.000121	0.00355	CcSEcCtD
Plerixafor—Headache—Vincristine—sarcoma	0.00012	0.00354	CcSEcCtD
Plerixafor—Vomiting—Mitoxantrone—sarcoma	0.000119	0.0035	CcSEcCtD
Plerixafor—Rash—Mitoxantrone—sarcoma	0.000118	0.00347	CcSEcCtD
Plerixafor—Dermatitis—Mitoxantrone—sarcoma	0.000118	0.00347	CcSEcCtD
Plerixafor—Headache—Mitoxantrone—sarcoma	0.000117	0.00345	CcSEcCtD
Plerixafor—Hypersensitivity—Etoposide—sarcoma	0.000115	0.00337	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FLT1—sarcoma	0.000114	0.00304	CbGpPWpGaD
Plerixafor—Haemoglobin—Doxorubicin—sarcoma	0.000114	0.00336	CcSEcCtD
Plerixafor—Nausea—Vincristine—sarcoma	0.000114	0.00336	CcSEcCtD
Plerixafor—CXCR4—Disease—FOXO1—sarcoma	0.000114	0.00303	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PDGFRB—sarcoma	0.000114	0.00303	CbGpPWpGaD
Plerixafor—Haemorrhage—Doxorubicin—sarcoma	0.000114	0.00334	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PLCG1—sarcoma	0.000112	0.00299	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PDGFRA—sarcoma	0.000112	0.00298	CbGpPWpGaD
Plerixafor—Asthenia—Etoposide—sarcoma	0.000112	0.00328	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—sarcoma	0.000112	0.00328	CcSEcCtD
Plerixafor—Nausea—Mitoxantrone—sarcoma	0.000111	0.00327	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—sarcoma	0.000111	0.00326	CcSEcCtD
Plerixafor—Pruritus—Etoposide—sarcoma	0.00011	0.00324	CcSEcCtD
Plerixafor—Mental disorder—Epirubicin—sarcoma	0.000108	0.00316	CcSEcCtD
Plerixafor—Erythema—Epirubicin—sarcoma	0.000107	0.00314	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ATF1—sarcoma	0.000107	0.00284	CbGpPWpGaD
Plerixafor—Diarrhoea—Etoposide—sarcoma	0.000107	0.00313	CcSEcCtD
Plerixafor—Flatulence—Epirubicin—sarcoma	0.000105	0.0031	CcSEcCtD
Plerixafor—Dizziness—Etoposide—sarcoma	0.000103	0.00303	CcSEcCtD
Plerixafor—Immune system disorder—Doxorubicin—sarcoma	0.000103	0.00302	CcSEcCtD
Plerixafor—Mental disorder—Doxorubicin—sarcoma	9.96e-05	0.00293	CcSEcCtD
Plerixafor—Ill-defined disorder—Epirubicin—sarcoma	9.92e-05	0.00292	CcSEcCtD
Plerixafor—Vomiting—Etoposide—sarcoma	9.9e-05	0.00291	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—sarcoma	9.89e-05	0.00291	CcSEcCtD
Plerixafor—Rash—Etoposide—sarcoma	9.82e-05	0.00289	CcSEcCtD
Plerixafor—Dermatitis—Etoposide—sarcoma	9.81e-05	0.00288	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CREB1—sarcoma	9.79e-05	0.00261	CbGpPWpGaD
Plerixafor—Headache—Etoposide—sarcoma	9.75e-05	0.00287	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—sarcoma	9.75e-05	0.00287	CcSEcCtD
Plerixafor—Malaise—Epirubicin—sarcoma	9.64e-05	0.00283	CcSEcCtD
Plerixafor—Syncope—Epirubicin—sarcoma	9.59e-05	0.00282	CcSEcCtD
Plerixafor—Loss of consciousness—Epirubicin—sarcoma	9.4e-05	0.00276	CcSEcCtD
Plerixafor—Nausea—Etoposide—sarcoma	9.25e-05	0.00272	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—sarcoma	9.18e-05	0.0027	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—sarcoma	9.1e-05	0.00268	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	9.04e-05	0.00266	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—sarcoma	9e-05	0.00264	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—sarcoma	8.92e-05	0.00262	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—sarcoma	8.9e-05	0.00262	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—sarcoma	8.87e-05	0.00261	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—sarcoma	8.73e-05	0.00257	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—sarcoma	8.7e-05	0.00256	CcSEcCtD
Plerixafor—CXCR4—Disease—KIT—sarcoma	8.68e-05	0.00231	CbGpPWpGaD
Plerixafor—Shock—Epirubicin—sarcoma	8.59e-05	0.00252	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—sarcoma	8.56e-05	0.00252	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—sarcoma	8.48e-05	0.00249	CcSEcCtD
Plerixafor—Hyperhidrosis—Epirubicin—sarcoma	8.44e-05	0.00248	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—sarcoma	8.42e-05	0.00248	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—IGF1R—sarcoma	8.38e-05	0.00223	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	8.37e-05	0.00246	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—sarcoma	8.32e-05	0.00245	CcSEcCtD
Plerixafor—CXCR4—Disease—CREB1—sarcoma	8.26e-05	0.0022	CbGpPWpGaD
Plerixafor—Dry mouth—Doxorubicin—sarcoma	8.24e-05	0.00242	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—sarcoma	8.08e-05	0.00237	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FOXO1—sarcoma	7.97e-05	0.00212	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—sarcoma	7.97e-05	0.00212	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDGFRB—sarcoma	7.96e-05	0.00212	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Epirubicin—sarcoma	7.95e-05	0.00234	CcSEcCtD
Plerixafor—Shock—Doxorubicin—sarcoma	7.94e-05	0.00234	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—sarcoma	7.92e-05	0.00233	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—sarcoma	7.89e-05	0.00232	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—sarcoma	7.84e-05	0.00231	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—sarcoma	7.84e-05	0.0023	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PDGFRA—sarcoma	7.84e-05	0.00209	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Doxorubicin—sarcoma	7.81e-05	0.00229	CcSEcCtD
Plerixafor—Dyspnoea—Epirubicin—sarcoma	7.78e-05	0.00229	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—sarcoma	7.68e-05	0.00226	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Epirubicin—sarcoma	7.53e-05	0.00222	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—sarcoma	7.52e-05	0.00221	CcSEcCtD
Plerixafor—Constipation—Epirubicin—sarcoma	7.46e-05	0.00219	CcSEcCtD
Plerixafor—Pain—Epirubicin—sarcoma	7.46e-05	0.00219	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—sarcoma	7.36e-05	0.00216	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—sarcoma	7.3e-05	0.00215	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—sarcoma	7.25e-05	0.00213	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL2—sarcoma	7.24e-05	0.00193	CbGpPWpGaD
Plerixafor—Dyspnoea—Doxorubicin—sarcoma	7.2e-05	0.00212	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—sarcoma	7.19e-05	0.00211	CcSEcCtD
Plerixafor—Gastrointestinal pain—Epirubicin—sarcoma	7.14e-05	0.0021	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—sarcoma	7.11e-05	0.00209	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—sarcoma	6.97e-05	0.00205	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—sarcoma	6.96e-05	0.00205	CcSEcCtD
Plerixafor—Urticaria—Epirubicin—sarcoma	6.93e-05	0.00204	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—sarcoma	6.91e-05	0.00203	CcSEcCtD
Plerixafor—Pain—Doxorubicin—sarcoma	6.91e-05	0.00203	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—sarcoma	6.9e-05	0.00203	CcSEcCtD
Plerixafor—CXCR4—Disease—MDM2—sarcoma	6.83e-05	0.00182	CbGpPWpGaD
Plerixafor—Feeling abnormal—Doxorubicin—sarcoma	6.65e-05	0.00196	CcSEcCtD
Plerixafor—Gastrointestinal pain—Doxorubicin—sarcoma	6.6e-05	0.00194	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—KDR—sarcoma	6.6e-05	0.00176	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—sarcoma	6.43e-05	0.00189	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—sarcoma	6.42e-05	0.00189	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—sarcoma	6.38e-05	0.00188	CcSEcCtD
Plerixafor—Asthenia—Epirubicin—sarcoma	6.26e-05	0.00184	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—sarcoma	6.17e-05	0.00182	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—KIT—sarcoma	6.08e-05	0.00162	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—sarcoma	6.08e-05	0.00162	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—sarcoma	5.97e-05	0.00176	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—sarcoma	5.95e-05	0.00175	CcSEcCtD
Plerixafor—CXCR4—Disease—CTNNB1—sarcoma	5.89e-05	0.00157	CbGpPWpGaD
Plerixafor—Asthenia—Doxorubicin—sarcoma	5.79e-05	0.0017	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CREB1—sarcoma	5.78e-05	0.00154	CbGpPWpGaD
Plerixafor—Dizziness—Epirubicin—sarcoma	5.77e-05	0.0017	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—sarcoma	5.71e-05	0.00168	CcSEcCtD
Plerixafor—Vomiting—Epirubicin—sarcoma	5.55e-05	0.00163	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—sarcoma	5.54e-05	0.00147	CbGpPWpGaD
Plerixafor—Diarrhoea—Doxorubicin—sarcoma	5.53e-05	0.00162	CcSEcCtD
Plerixafor—Rash—Epirubicin—sarcoma	5.5e-05	0.00162	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—sarcoma	5.5e-05	0.00162	CcSEcCtD
Plerixafor—Headache—Epirubicin—sarcoma	5.47e-05	0.00161	CcSEcCtD
Plerixafor—Dizziness—Doxorubicin—sarcoma	5.34e-05	0.00157	CcSEcCtD
Plerixafor—CXCR4—Disease—SRC—sarcoma	5.33e-05	0.00142	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—sarcoma	5.23e-05	0.00139	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—sarcoma	5.18e-05	0.00152	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—sarcoma	5.13e-05	0.00151	CcSEcCtD
Plerixafor—CXCR4—Disease—NRAS—sarcoma	5.13e-05	0.00136	CbGpPWpGaD
Plerixafor—Rash—Doxorubicin—sarcoma	5.09e-05	0.0015	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—sarcoma	5.09e-05	0.0015	CcSEcCtD
Plerixafor—Headache—Doxorubicin—sarcoma	5.06e-05	0.00149	CcSEcCtD
Plerixafor—Nausea—Doxorubicin—sarcoma	4.8e-05	0.00141	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—MDM2—sarcoma	4.79e-05	0.00127	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—sarcoma	4.77e-05	0.00127	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—sarcoma	4.67e-05	0.00124	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—sarcoma	4.45e-05	0.00118	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—sarcoma	4.41e-05	0.00117	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—sarcoma	4.28e-05	0.00114	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—sarcoma	4.17e-05	0.00111	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JUN—sarcoma	4.16e-05	0.00111	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—sarcoma	4.13e-05	0.0011	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—sarcoma	3.75e-05	0.000998	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SRC—sarcoma	3.73e-05	0.000993	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—sarcoma	3.63e-05	0.000967	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—sarcoma	3.59e-05	0.000956	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—sarcoma	3.34e-05	0.00089	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—sarcoma	3.27e-05	0.000871	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—sarcoma	3.09e-05	0.000822	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—sarcoma	2.75e-05	0.000731	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—sarcoma	2.63e-05	0.000699	CbGpPWpGaD
